Host cell protein control in cell-derived products

 

Host cell proteins (HCPs) represent one of the most closely monitored impurity classes in biopharmaceutical manufacturing. These proteins originate from the production host and can carry through multiple downstream purification steps if not adequately removed. For cell-derived products such as monoclonal antibodies, recombinant proteins, and other biologics, effective HCP control is both a regulatory requirement and a critical component of product quality assurance.

 

Residual HCPs can pose several risks, including immunogenic responses in patients, degradation of the drug product through enzymatic activity, and interference with product stability or efficacy. As bioprocessing strategies continue to evolve toward scale-up and more complex manufacturing platforms, analytical methods for detecting and quantifying HCPs remain essential throughout process development, purification, and lot release testing.¹

 

Why CHO HCP detection matters

Host cell proteins encompass a heterogeneous mixture of proteins expressed by the production cell line during upstream culture. In mammalian expression systems, Chinese hamster ovary (CHO) cells are the most widely used hosts, making CHO-derived HCPs particularly relevant to biopharmaceutical manufacturers.

 

CHO HCPs include intracellular enzymes, structural proteins, and secreted factors that may co-purify with the therapeutic molecule due to shared physicochemical properties. While purification processes are designed to remove the majority of these contaminants, trace levels often remain. Even low concentrations of certain HCPs can negatively affect product safety or stability, particularly proteases and other enzymatically active species.²

 

Because of the diversity and variability of HCP populations, analytical methods must provide broad coverage while maintaining sensitivity at low nanogram per milliliter levels. Regulatory agencies expect manufacturers to demonstrate process understanding and consistent HCP clearance across development stages, reinforcing the need for reliable quantitative assays.

 

ELISA for accurate quantification of HCP

 

Among available analytical approaches, enzyme-linked immunosorbent assays (ELISAs) have become the primary method for routine HCP quantification. ELISA offers several advantages over orthogonal techniques such as Western blotting, including quantitative accuracy, higher sensitivity, and substantially reduced time to results.

 

Broad coverage HCP ELISAs use polyclonal antibody reagents raised against representative host cell protein mixtures. When properly validated, these assays provide a robust estimate of total residual HCP content across a wide dynamic range. In contrast, Western blotting remains largely qualitative or semi-quantitative and is primarily used for coverage assessment rather than routine monitoring.³

 

From a workflow perspective, ELISA is also significantly more efficient. When using a pre-coated ELISA kit, total assay time is approximately 4.5 hours from sample addition to data analysis. Western blot workflows frequently require two to three days, accounting for gel electrophoresis, membrane transfer, blocking, antibody incubation, imaging, and data interpretation.

 

BioLegend’s New LEGEND MAX CHO HCP (Host Cell Protein) ELISA Kit

 

To help bioprocessing teams generate reliable HCP data faster and with greater confidence, we are pleased to announce the launch of the new LEGEND MAX™ CHO HCP (Host Cell Protein) ELISA Kit. This assay was developed to support routine HCP monitoring across process development, downstream purification, and quality control workflows.

 

Built on a pre-coated ELISA format, the kit delivers quantitative HCP results in approximately 4.5 hours, enabling same-day decision making without sacrificing analytical performance. The assay is designed for broad CHO HCP coverage and provides sensitivity and a dynamic range suitable for both in-process samples and highly purified drug substances.

 

ELISA kit performance and comparative evaluation

 

Not all HCP ELISA kits perform equally, making kit selection an important consideration. Key performance characteristics include assay sensitivity, dynamic range, reproducibility, and total time to results.

 

Sensitivity and dynamic range

 

Comparative evaluation demonstrated that our LEGEND MAX CHO HCP ELISA kit consistently detected low level CHO HCP across the full tested concentration range. Signal response remained linear across multiple orders of magnitude, supporting confident quantification for both in process and final drug substance samples. Performance trends were comparable to a leading commercially available competitor kit when tested on matched sample dilutions.

 

Sample concentration of CHO HCP in cell culture supernatant between a competitor CHO-HCP ELISA kit and LEGEND MAX CHO HCP (Host Cell Protein) Kit. Three CHO-K1 derived cell lines (CHO Cell 1-3) were seeded at a density of 0.2-0.3 x 10⁶ cells/mL and incubated for 3-4 days before collecting supernatant. Supernatant samples were diluted appropriately before performing the ELISA assay using the LEGEND MAX CHO HCP (Host Cell Protein) ELISA Kit (Cat. No. 479107) or competitor ELISA kit. Data represents compiled data from three technical replicates for each cell line.

 

Sample Type	Linearity (%) LEGEND MAX CHO HCP ELISA Kit	Linearity (%) Competitor CHO HCP ELISA Kit
CHO Cell 1	100	107
CHO Cell 2	100	104
CHO Cell 3	100	110

Conditional media from CHO-K1-derived cell lines were serially diluted two-fold to produce samples with concentrations within the dynamic range. Then, linearity was analyzed with the LEGEND MAX CHO HCP (Host Cell Protein) ELISA kit or Competitor CHO HCP ELISA kit.

 

The minimum detectable concentration of CHO HCP using the LEGEND MAX CHO HCP (Host Cell Protein) ELISA Kit is 1.07 ng/mL. Our kit offers comparable sensitivity to the competitor kit (Competitor CHO-HCP ELISA Kit LLOD ~1 ng/mL).

 

Reproducibility and assay precision

 

Intra-assay and inter-assay variability analyses showed low coefficient of variation values across independent runs, supporting reliable analysis and minimizing the need for repeat testing due to assay variability.

 

Concentration	Sample 1	Sample 2
Number of Replicates	16	16
Mean Concentration (ng/mL)	203.6	17.4
Standard Deviation	18.1	1.8
% CV	8.9	10.3

Sixteen replicates each of two samples containing different CHO HCP concentrations were tested in one assay.

 

Concentration	Sample 1	Sample 2
Number of Replicates	10	10
Mean Concentration (ng/mL)	160.6	15.9
Standard Deviation	25.4	1.6
% CV	15	10

Two samples containing different concentrations of CHO HCP were tested in ten independent assays.

 

Sample dilution and quantitative agreement

 

When evaluating identical samples at equivalent dilution factors, measured HCP concentrations aligned closely with those generated using a competitor ELISA kit. This indicates that improved workflow efficiency does not come at the expense of quantitative accuracy.

 

Time to results and operational efficiency

 

The precoated ELISA format offers same day results with a total assay time of approximately 4.5 hours. This represents a meaningful reduction in turnaround time compared to membrane-based methods and supports faster decision-making during process development and quality control activities.

 

Summary

 

Effective host cell protein monitoring is a foundational requirement for the development and manufacture of safe, high-quality biologics. CHO-derived HCPs present unique analytical challenges due to their potential impact on product performance. ELISAs continue to serve as the preferred method for routine HCP quantification because it delivers sensitivity, reproducibility, and quantitative data within a practical timeframe.

 

Precoated ELISA kits further streamline HCP analysis by combining consistent performance with simplified workflows and same day results. When supported by comparative performance evaluation, these assays enable manufacturers to maintain control over HCP clearance from early development through commercial production.

 

As CHO cell lines continue to support biologics manufacturing, host cell protein monitoring remains an important control point for product quality and regulatory compliance. The launch of our new LEGEND MAX ELISA kit supports this by providing a solution for detecting residual process‑related impurities across downstream cell manufacturing workflows. Our assay enables sensitive, reproducible measurement of CHO HCPs from early process development through late‑stage purification and lot release testing. This empowers bioprocessing scientists to strengthen risk mitigation strategies, improves comparability across runs, and supports every part of the bioprocessing workflow.

 

Whether you’re optimizing upstream processes or preparing for GMP production, BioLegend offers custom bioprocessing services to support your program’s unique needs. Explore Cell Vive™ GMP Custom Services for scalable, GMP-compliant solutions that bridge early research, process development, and cell manufacturing.

 

References

 

1. Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC. 2005. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog. Jan-Feb;21(1):122-33. doi: 10.1021/bp049780w. PMID: 15903249. https://pubmed.ncbi.nlm.nih.gov/15903249/
2. Bracewell, D.G., Francis, R. and Smales, C.M. 2015. The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control. Biotechnol. Bioeng., 112: 1727-1737. https://doi.org/10.1002/bit.25628
3. Ito T, Lutz H, Tan L, et al. 2024. Host cell proteins in monoclonal antibody processing: Control, detection, and removal. Biotechnol. Prog. 40(4):e3448. doi:10.1002/btpr.3448 https://aiche.onlinelibrary.wiley.com/doi/10.1002/btpr.3448
4. Bio Connect. 2022. The Complete Guide to Host Cell Protein ELISA. https://www.bio-connect.nl/news/the-complete-guide-to-host-cell-protein-elisa/